Literature DB >> 2795453

Evaluation of theophylline pharmacokinetics in a pediatric population using mixed effects models.

M S Driscoll1, T M Ludden, D T Casto, L C Littlefield.   

Abstract

Routine clinical pharmacokinetic data collected prospectively from pediatric patients receiving theophylline were analyzed using the NONMEM (nonlinear mixed effects model) digital computer program. A total of 314 measured serum theophylline concentrations (STCs) were obtained from 84 hospitalized patients ranging in age from 4 months to 15.2 years with the majority of patients between the ages of 1 and 8 years. Fifty-six percent were male. The race/ethnicity distribution was 71.4% Latin, 15.5% black, 11.9% Caucasian, and 1.2% (one subject) Pakistani. Of the total number of observed STCs, 16.2% reflected some degree of outpatient dosing. The pharmacokinetic model used was a one-compartment open model with either zero-order or first-order absorption and first-order elimination. Age was the most important determinant of theophylline clearance (Cl); weight was inferior to age and did not statistically improve the model (p greater than 0.005) when combined with age. Total Cl increased by 10%/year over the age range of 1 to 15 years of age. Black race and male gender were associated with higher Cl values: for a given age, Cl was 34% higher for blacks than the reference population composed of the remaining patients, and Cl for males was 25% higher than that for females. The volume of distribution (Vd) for the population was estimated to be 0.62 L/kg. The interindividual variability in Cl and Vd expressed as coefficients of variation were 19 and 28%, respectively. The residual intraindividual error variance corresponded to a standard deviation of 2.8 micrograms/ml. The STCs that represented some degree of outpatient dosing were 21% lower than those reflecting only inpatient dosing. Alternate models that include weight as a determinant of theophylline clearance are also provided. The NONMEM method of determining population pharmacokinetics is well suited to the pediatric population since it does not require a large number of STCs per patient. In this study a mean of only 3.7 STCs per patient were utilized to provide information which should prove useful in the design and adjustment of theophylline dosage regimens in children.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2795453     DOI: 10.1007/bf01059025

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  45 in total

1.  Relationship of theophylline clearance to oral dosage in children with chronic asthma.

Authors:  E Ginchansky; M Weinberger
Journal:  J Pediatr       Date:  1977-10       Impact factor: 4.406

2.  Rational intravenous doses of theophylline.

Authors:  P A Mitenko; R I Ogilvie
Journal:  N Engl J Med       Date:  1973-09-20       Impact factor: 91.245

3.  Reduction of serum theophylline levels by terbutaline in children with asthma.

Authors:  Y Danziger; M Garty; B Volwitz; D Ilfeld; I Varsano; J B Rosenfeld
Journal:  Clin Pharmacol Ther       Date:  1985-04       Impact factor: 6.875

4.  Influence of gender on theophylline dosage requirements in children with chronic asthma.

Authors:  L Hendeles; L Vaughan; M Weinberger; G Smith
Journal:  Drug Intell Clin Pharm       Date:  1981-05

5.  Clinical and bronchodilating efficacy of controlled-release theophylline as a function of its serum concentrations in preschool children.

Authors:  H J Neijens; E J Duiverman; B H Graatsma; K F Kerrebijn
Journal:  J Pediatr       Date:  1985-11       Impact factor: 4.406

Review 6.  A clinical and pharmacokinetic basis for the selection and use of slow release theophylline products.

Authors:  L Hendeles; R P Iafrate; M Weinberger
Journal:  Clin Pharmacokinet       Date:  1984 Mar-Apr       Impact factor: 6.447

7.  Nonlinear theophylline elimination.

Authors:  D D Tang-Liu; R L Williams; S Riegelman
Journal:  Clin Pharmacol Ther       Date:  1982-03       Impact factor: 6.875

8.  Pharmacokinetics of theophylline in hepatic disease.

Authors:  A Mangione; T E Imhoff; R V Lee; L Y Shum; W J Jusko
Journal:  Chest       Date:  1978-05       Impact factor: 9.410

9.  Total theophylline clearance in childhood: the influence of age-dependent changes in metabolism and elimination.

Authors:  D Berdel; R Süverkrüp; G Heimann; A von Berg; N Liappis; A Stühmer
Journal:  Eur J Pediatr       Date:  1987-01       Impact factor: 3.183

Review 10.  Genetically determined variability in acetylation and oxidation. Therapeutic implications.

Authors:  D W Clark
Journal:  Drugs       Date:  1985-04       Impact factor: 9.546

View more
  13 in total

1.  Drug-drug pharmacodynamic interaction detection by a nonparametric population approach. Influence of design and of interindividual variability.

Authors:  Y Merlé; A Mallet; E Schmautz
Journal:  J Pharmacokinet Biopharm       Date:  1999-10

2.  Smooth nonparametric maximum likelihood estimation for population pharmacokinetics, with application to quinidine.

Authors:  M Davidian; A R Gallant
Journal:  J Pharmacokinet Biopharm       Date:  1992-10

3.  Evaluation of hypothesis testing for comparing two populations using NONMEM analysis.

Authors:  D B White; C A Walawander; D Y Liu; T H Grasela
Journal:  J Pharmacokinet Biopharm       Date:  1992-06

Review 4.  Bayesian parameter estimation and population pharmacokinetics.

Authors:  A H Thomson; B Whiting
Journal:  Clin Pharmacokinet       Date:  1992-06       Impact factor: 6.447

5.  Population pharmacokinetics: theory and practice.

Authors:  L Aarons
Journal:  Br J Clin Pharmacol       Date:  1991-12       Impact factor: 4.335

Review 6.  Sparse data analysis.

Authors:  L Aarons
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1993 Jan-Mar       Impact factor: 2.441

7.  Theophylline Population Pharmacokinetics and Dosing in Children Following Congenital Heart Surgery With Cardiopulmonary Bypass.

Authors:  Adam Frymoyer; Felice Su; Paul C Grimm; Scott M Sutherland; David M Axelrod
Journal:  J Clin Pharmacol       Date:  2016-02-18       Impact factor: 3.126

8.  Population pharmacokinetics of theophylline during paediatric extracorporeal membrane oxygenation.

Authors:  Hussain Mulla; Fazal Nabi; Sanjiv Nichani; Graham Lawson; R K Firmin; David R Upton
Journal:  Br J Clin Pharmacol       Date:  2003-01       Impact factor: 4.335

9.  Comparison of CYP1A2 and NAT2 phenotypes between black and white smokers.

Authors:  Joshua E Muscat; Brian Pittman; Wayne Kleinman; Philip Lazarus; Steven D Stellman; John P Richie
Journal:  Biochem Pharmacol       Date:  2008-07-25       Impact factor: 5.858

10.  The population pharmacokinetics of long-term methotrexate in rheumatoid arthritis.

Authors:  C Godfrey; K Sweeney; K Miller; R Hamilton; J Kremer
Journal:  Br J Clin Pharmacol       Date:  1998-10       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.